PARP inhibitors in prostate cancer: What nurses need to know

COR2ED Medical Education: Pablo Peinado, Research Nurse Coordinator, and Dr. Elena Castro, medical oncologist, who both work at Hospital Universitario Virgen de la Victoria in Malaga in Spain, discuss ‘The potential of PARP inhibitors in prostate cancer: What nurses need to know’. 

In this podcast, the experts discuss PARP inhibitors (PARPi’s), how they work and key data from the registration trials for rucaparib and olaparib, TRITON2 and PROfound.  They also discuss how to select PARPi’s for their prostate cancer patients and where they fit in the overall treatment sequence. Pablo provides some insight into communicating with patients, and the types of questions and concerns they often have in relation to genetic testing and treatment with PARPi’s.  In addition, they also discuss the PARPi’s currently in late-stage development such as niraparib and talazoparib as well as the potential future use of PARPi’s in combination with immunotherapies or androgen receptor pathway inhibitors.